Translational proteomics in Alzheimer's disease and related disorders

Clinical Biochemistry

Volumn 46, Issue 6, 2013, Pages 480-486

  Ghidoni, Roberta ^a   Paterlini, Anna ^a   Benussi, Luisa ^a  

^a IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

Author keywords

Alzheimer's disease; Biomarker; Blood; Cerebrospinal fluid; Circulating; Dementia; Frontotemporal; Plasma; Presymptomatic; Proteome

Indexed keywords

BIOLOGICAL MARKER; PROTEIN; PROTEOME; TAU PROTEIN;

ALZHEIMER DISEASE; DEMENTIA; DISEASE ASSOCIATION; ENDOPHENOTYPE; FRONTOTEMPORAL DEMENTIA; HUMAN; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROTEOMICS; REVIEW; TRANSLATIONAL RESEARCH; BLOOD; CEREBROSPINAL FLUID; DIFFERENTIAL DIAGNOSIS; GENETICS; LONGITUDINAL STUDY;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; FRONTOTEMPORAL DEMENTIA; HUMANS; LONGITUDINAL STUDIES; NEUROPSYCHOLOGICAL TESTS; PROTEOMICS; TAU PROTEINS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84886747916     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.10.012     Document Type: Review

References (114)

1. McKeith I.G., Galasko D., Kosaka K., Perry E.K., Dickson D.W., Hansen L.A., et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996, 47:1113-1124.
2. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
3. Graff-Radford N.R., Woodruff B.K. Frontotemporal dementia. Semin Neurol 2007, 27:48-57.
4. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999, 56:303-308.
5. Petersen R.C., Doody R., Kurz A., Mohs R.C., Morris J.C., Rabins P.V., et al. Current concepts in mild cognitive impairment. Arch Neurol 2001, 58:1985-1992.
6. DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol 2003, 2:15-21.
7. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
8. Dubois B., Feldman H.H., Jacova C., Dekosky S.T., Barberger-Gateau P., Cummings J., et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007, 6:734-746.
9. Dubois B., Feldman H.H., Jacova C., Cummings J.L., Dekosky S.T., Barberger-Gateau P., et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010, 9:1118-1127.
10. Grundke-Iqbal I., Iqbal K., Tung Y.C., Quinlan M., Wisniewski H.M., Binder L.I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 1986, 83:4913-4917.
11. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
12. McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:263-269.
13. Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:270-279.
14. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:280-292.
15. Blennow K., Hampel H., Weiner M., Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010, 6:131-144.
16. Mattsson N., Zetterberg H., Hansson O., Andreasen N., Parnetti L., Jonsson M., et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009, 302:385-393.
17. Visser P.J., Verhey F., Knol D.L., Scheltens P., Wahlund L.O., Freund-Levi Y., et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 2009, 8:619-627.
18. Shaw L.M., Vanderstichele H., Knapik-Czajka M., Clark C.M., Aisen P.S., Petersen R.C., et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009, 65:403-413.
19. Frisoni G.B., Prestia A., Zanetti O., Galluzzi S., Romano M., Cotelli M., et al. Markers of Alzheimer's disease in a population attending a memory clinic. Alzheimers Dement 2009, 5:307-317.
20. Galluzzi S., Geroldi C., Ghidoni R., Paghera B., Amicucci G., Bonetti M., et al. The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment. J Neurol 2010, 257:2004-2014.
21. Fagan A.M., Head D., Shah A.R., Marcus D., Mintun M., Morris J.C., et al. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 2009, 65:176-183.
22. Roe C.M., Fagan A.M., Williams M.M., Ghoshal N., Aeschleman M., Grant E.A., et al. Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease. Neurology 2011, 76:501-510.
23. 42 is associated with cognitive impairment in healthy elderly and subjective cognitive impairment. J Alzheimers Dis 2011, 26:135-142.
24. Cedazo-Minguez A., Winblad B. Biomarkers for Alzheimer's disease and other forms of dementia: clinical needs, limitations and future aspects. Exp Gerontol 2010, 45:5-14.
25. Hampel H., Blennow K., Shaw L.M., Hoessler Y.C., Zetterberg H., Trojanowski J.Q. Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol 2010, 45:30-40.
26. Blennow K., Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003, 2:605-613.
27. Sunderland T., Linker G., Mirza N., Putnam K.T., Friedman D.L., Kimmel L.H., et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003, 289:2094-2103.
28. Buerger K., Frisoni G., Uspenskaya O., Ewers M., Zetterberg H., Geroldi C., et al. Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). Exp Gerontol 2009, 44:579-585.
29. Bjerke M., Portelius E., Minthon L., Wallin A., Anckarsäter H., Anckarsäter R., et al. Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int J Alzheimers Dis 2010, 2010:986310.
30. Mattsson N., Andreasson U., Persson S., Arai H., Batish S.D., Bernardini S., et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 2011, 7:386-395.
31. Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998, 51:1546-1554.
32. DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011, 72:245-256.
33. Renton A.E., Majounie E., Waite A., Simón-Sánchez J., Rollinson S., Gibbs J.R., et al. A exanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011, 72:257-268.
34. Seelaar H., Rohrer J.D., Pijnenburg Y.A., Fox N.C., van Swieten J.C. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry 2011, 82:476-486.
35. Baker M., Mackenzie I.R., Pickering-Brown S.M., Gass J., Rademakers R., Lindholm C., et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006, 442:916-919.
36. Cruts M., Gijselinck I., van der Zee J., Engelborghs S., Wils H., Pirici D., et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 2006, 442:920-924.
37. Benussi L., Binetti G., Sina E., Gigola L., Bettecken T., Meitinger T., et al. A novel deletion in progranulin gene is associated with FTDP-17 and CBS. Neurobiol Aging 2008, 29:427-435.
38. Cairns N.J., Bigio E.H., Mackenzie I.R., Neumann M., Lee V.M., Hatanpaa K.J., et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 2007, 114:5-22.
39. Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011, 134:2456-2477.
40. Ghidoni R., Paterlini A., Albertini V., Binetti G., Benussi L. Losing protein in the brain: the case of progranulin. Brain Res 2012, 1476:172-182.
41. Ghidoni R., Benussi L., Glionna M., Franzoni M., Binetti G. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology 2008, 71:1235-1239.
42. Sleegers K., Brouwers N., Van Damme P., Engelborghs S., Gijselinck I., van der Zee J., et al. Serum biomarker for progranulin-associated frontotemporal lobar degeneration. Ann Neurol 2009, 65:603-609.
43. Finch N., Baker M., Crook R., Swanson K., Kuntz K., Surtees R., et al. Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain 2009, 132:583-591.
44. Ghidoni R., Stoppani E., Rossi G., Piccoli E., Albertini V., Paterlini A., et al. Optimal plasma progranulin cutoff value for predicting null progranulin mutations in neurodegenerative diseases: a multicenter Italian study. Neurodegener Dis 2012, 9:121-127.
45. Haass C., Schlossmacher M.G., Hung A.Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B.L., et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 1992, 359:322-325.
46. Sisodia S.S. Beta-amyloid precursor protein cleavage by a membrane-bound protease. Proc Natl Acad Sci U S A 1992, 89:6075-6079.
47. Ghidoni R., Paterlini A., Albertini V., Stoppani E., Binetti G., Fuxe K., et al. A window into the heterogeneity of human cerebrospinal fluid Aβ peptides. J Biomed Biotechnol 2011, 2011:697036.
48. Portelius E., Mattsson N., Andreasson U., Blennow K., Zetterberg H. Novel aβ isoforms in Alzheimer's disease-their role in diagnosis and treatment. Curr Pharm Des 2011, 17:2594-2602.
49. Bibl M., Gallus M., Welge V., Lehmann S., Sparbier K., Esselmann H., et al. Characterization of cerebrospinal fluid aminoterminally truncated and oxidized amyloid-β peptides. Proteomics Clin Appl 2012, 6:163-169.
50. Bibl M., Gallus M., Welge V., Esselmann H., Wiltfang J. Aminoterminally truncated and oxidized amyloid-β peptides in the cerebrospinal fluid of Alzheimer's disease patients. J Alzheimers Dis 2012, 29:809-816.
51. Ghidoni R., Albertini V., Squitti R., Paterlini A., Bruno A., Bernardini S., et al. Novel T719P AbetaPP mutation unbalances the relative proportion of amyloid-beta peptides. J Alzheimers Dis 2009, 18:295-303.
52. Portelius E., Andreasson U., Ringman J.M., Buerger K., Daborg J., Buchhave P., et al. Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease. Mol Neurodegener 2010, 5:2.
53. Portelius E., Fortea J., Molinuevo J.L., Gustavsson M.K., Andreasson U., Sanchez-Valle R. The amyloid-β isoform pattern in cerebrospinal fluid in familial PSEN1 M139T- and L286P-associated Alzheimer's disease. Mol Med Rep 2012, 5:1111-1115.
54. Portelius E., Dean R.A., Gustavsson M.K., Andreasson U., Zetterberg H., Siemers E., et al. A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease. Alzheimers Res Ther 2010, 2:2-7.
55. Portelius E., Zetterberg H., Dean R.A., Marcil A., Bourgeois P., Nutu M., et al. Amyloid-β1-15/16 as a marker for γ-secretase inhibition in Alzheimer's disease. J Alzheimers Dis 2012, 31:335-341.
56. Bibl M., Mollenhauer B., Wolf S., Esselmann H., Lewczuk P., Kornhuber J., et al. Reduced CSF carboxyterminally truncated Abeta peptides in frontotemporal lobe degenerations. J Neural Transm 2007, 114:621-628.
57. Bibl M., Gallus M., Welge V., Esselmann H., Wolf S., Rüther E., et al. Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia. J Neural Transm 2012, 119:805-813.
58. Bibl M., Mollenhauer B., Esselmann H., Lewczuk P., Trenkwalder C., Brechlin P., et al. CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies. J Neural Transm 2006, 113:1771-1778.
59. Hesse C., Nilsson C.L., Blennow K., Davidsson P. Identification of the apolipoprotein E4 isoform in cerebrospinal fluid with preparative two-dimensional electrophoresis and matrix assisted laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 2001, 22:1834-1837.
60. Davidsson P., Westman-Brinkmalm A., Nilsson C.L., Lindbjer M., Paulson L., Andreasen N., et al. Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport 2002, 13:611-615.
61. Choe L.H., Dutt M.J., Relkin N., Lee K.H. Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease. Electrophoresis 2002, 23:2247-2251.
62. Puchades M., Hansson S.F., Nilsson C.L., Andreasen N., Blennow K., Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res 2003, 118:140-146.
63. Carrette O., Demalte I., Scherl A., Yalkinoglu O., Corthals G., Burkhard P., et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 2003, 3:1486-1494.
64. Korolainen M.A., Nyman T.A., Nyyssönen P., Hartikainen E.S., Pirttilä T. Multiplexed proteomic analysis of oxidation and concentrations of cerebrospinal fluid proteins in Alzheimer disease. Clin Chem 2007, 53:657-665.
65. Finehout E.J., Franck Z., Choe L.H., Relkin N., Lee K.H. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann Neurol 2007, 61:120-129.
66. Sihlbom C., Davidsson P., Sjögren M., Wahlund L.O., Nilsson C.L. Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer's disease patients and healthy individuals. Neurochem Res 2008, 33:1332-1340.
67. Zetterberg H., Rüetschi U., Portelius E., Brinkmalm G., Andreasson U., Blennow K., et al. Clinical proteomics in neurodegenerative disorders. Acta Neurol Scand 2008, 118:1-11.
68. Simonsen A.H., McGuire J., Podust V.N., Davies H., Minthon L., Skoog I., et al. Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease. Neurobiol Aging 2008, 29:961-968.
69. Zhang J., Sokal I., Peskind E.R., Quinn J.F., Jankovic J., Kenney C., et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol 2008, 129:526-529.
70. Perrin R.J., Craig-Schapiro R., Malone J.P., Shah A.R., Gilmore P., Davis A.E., et al. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS One 2011, 6:e16032.
71. Jahn H., Wittke S., Zürbig P., Raedler T.J., Arlt S., Kellmann M., et al. Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers. PLoS One 2011, 6:e26540.
72. Craig-Schapiro R., Kuhn M., Xiong C., Pickering E.H., Liu J., Misko T.P., et al. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS One 2011, 6:e18850.
73. Hu W.T., Chen-Plotkin A., Arnold S.E., Grossman M., Clark C.M., Shaw L.M., et al. Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol 2010, 119:669-678.
74. Davidsson P., Sjögren M., Andreasen N., Lindbjer M., Nilsson C.L., Westman-Brinkmalm A., et al. Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins. Brain Res Mol Brain Res 2002, 109:128-133.
75. Hansson S.F., Puchades M., Blennow K., Sjögren M., Davidsson P. Validation of a prefractionation method followed by two-dimensional electrophoresis-applied to cerebrospinal fluid proteins from frontotemporal dementia patients. Proteome Sci 2004, 2:7.
76. Simonsen A.H., McGuire J., Podust V.N., Hagnelius N.O., Nilsson T.K., Kapaki E., et al. A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia. Dement Geriatr Cogn Disord 2007, 24:434-440.
77. Rüetschi U., Zetterberg H., Podust V.N., Gottfries J., Li S., Hviid Simonsen A., et al. Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Exp Neurol 2005, 196:273-281.
78. Abdi F., Quinn J.F., Jankovic J., McIntosh M., Leverenz J.B., Peskind E., et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 2006, 9:293-348.
79. Abraham J.D., Calvayrac-Pawlowski S., Cobo S., Salvetat N., Vicat G., Molina L., et al. Combined measurement of PEDF, haptoglobin and tau in cerebrospinal fluid improves the diagnostic discrimination between alzheimer's disease and other dementias. Biomarkers 2011, 16:161-171.
80. Castaño E.M., Roher A.E., Esh C.L., Kokjohn T.A., Beach T. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurol Res 2006, 28:155-163.
81. Roher A.E., Maarouf C.L., Sue L.I., Hu Y., Wilson J., Beach T.G. Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease. Biomarkers 2009, 14:493-501.
82. Mouton-Barbosa E., Roux-Dalvai F., Bouyssié D., Berger F., Schmidt E., Righetti P.G., et al. In-depth exploration of cerebrospinal fluid by combining peptide ligand library treatment and label-free protein quantification. Mol Cell Proteomics 2010, 9:1006-1021.
83. Thadikkaran L., Siegenthaler M.A., Crettaz D., Queloz P.A., Schneider P., Tissot J.D. Recent advances in blood-related proteomics. Proteomics 2005, 5:3019-3034.
84. Ray S., Reddy P.J., Jain R., Gollapalli K., Moiyadi A., Srivastava S. Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead. Proteomics 2011, 11:2139-2161.
85. Thambisetty M., Lovestone S. Blood-based biomarkers of Alzheimer's disease: challenging but feasible. Biomark Med 2010, 4:65-79.
86. Steinman L. Elaborate interactions between the immune and nervous systems. Nat Immunol 2004, 5:575-581.
87. Ray S., Britschgi M., Herbert C., Takeda-Uchimura Y., Boxer A., Blennow K., et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007, 13:1359-1362.
88. Britschgi M., Wyss-Coray T. Blood protein signature for the early diagnosis of Alzheimer disease. Arch Neurol 2009, 66:161-165.
89. Gómez Ravetti M., Moscato P. Identification of a 5-protein biomarker molecular signature for predicting Alzheimer's disease. PLoS One 2008, 3:e3111.
90. Soares H.D., Chen Y., Sabbagh M., Rohrer A., Schrijvers E., Breteler M. Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels. Ann N Y Acad Sci 2009, 1180:56-67.
91. O'Bryant S.E., Xiao G., Barber R., Reisch J., Doody R., Fairchild T., et al. A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol 2010, 67(9):1077-1081.
92. Marksteiner J., Kemmler G., Weiss E.M., Knaus G., Ullrich C., Mechtcheriakov S., et al. Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 2011, 32:539-540.
93. Johnstone D., Milward E.A., Berretta R., Moscato P. Alzheimer's Disease Neuroimaging Initiative. Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset. PLoS One 2012, 7:e34341.
94. Cox J., Heeren R.M., James P., Jorrin-Novo J.V., Kolker E., Levander F., et al. Facing challenges in proteomics today and in the coming decade: report of roundtable discussions at the 4th EuPA Scientific Meeting, Portugal, Estoril. J Proteomics 2011, 75:4-17.
95. Lee K.S., Chung J.H., Choi T.K., Suh S.Y., Oh B.H., Hong C.H. Peripheral cytokines and chemokines in Alzheimer's disease. Dement Geriatr Cogn Disord 2009, 28:281-287.
96. Hye A., Lynham S., Thambisetty M., Causevic M., Campbell J., Byers H.L., et al. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 2006, 129:3042-3050.
97. Thambisetty M., Simmons A., Hye A., Campbell J., Westman E., Zhang Y., et al. Plasma biomarkers of brain atrophy in Alzheimer's disease. PLoS One 2011, 6:e28527.
98. Zabel M., Schrag M., Mueller C., Zhou W., Crofton A., Petersen F., et al. Assessing candidate serum biomarkers for Alzheimer's disease: a longitudinal study. J Alzheimers Dis 2012, 30:311-321.
99. Rosén C., Mattsson N., Johansson P.M., Andreasson U., Wallin A., Hansson O., et al. Discriminatory analysis of biochip-derived protein patterns in CSF and plasma in neurodegenerative diseases. Front Aging Neurosci 2011, 3:1.
100. Foulds P., McAuley E., Gibbons L., Davidson Y., Pickering-Brown S.M., Neary D., et al. TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer's disease and frontotemporal lobar degeneration. Acta Neuropathol 2008, 116:141-146.
101. Williams R.J. Biochemical Individuality: The Basis for the Genetotrophic Concept 1956, John Wiley & Sons, New York.
102. Cotlove E., Harris E.K., Williams G.Z. Biological and analytic components of variation in long-term studies of serum constituents in normal subjects. 3 Physiological and medical implications. Clin Chem 1970, 16:1028-1032.
103. Harris E.K., Kanofsky P., Shakarji G., Cotlove E. Biological and analytic components of variation inlong-term studies of serum constituents in normal subjects.2 Estimating biological components of variation. Clin Chem 1970, 16:1022-1027.
104. Williams G.Z., Young D.S., Stein M.R., Cotlove E. Biological and analytic components of variation in long-term studies of serum constituents in normal subjects. 1 Objectives, subject selection, laboratory procedures, and estimation of analytic deviation. Clin Chem 1970, 16:1016-1021.
105. Harris E.K., Demets D.L. Biological and analytic components of variation in long-term studies of serum constituents in normal subjects. 5 Estimated biological variations in ionized calcium. Clin Chem 1971, 17:983-987.
106. Young D.S., Harris E.K., Cotlove E. Biological and analytic components of variation in long-term studies of serum constituents in normal subjects. 4 Results of a study design to eliminate long-term analytic deviations. Clin Chem 1971, 17:403-410.
107. Harris E.K. Effects of intraindividual and interindividual variation on appropriate use of normal ranges. Clin Chem 1974, 20:1535-1542.
108. Zhang J., Goodlett D.R., Peskind E.R., Quinn J.F., Zhou Y., Wang Q., et al. Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Neurobiol Aging 2005, 26:207-227.
109. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259.
110. Morris J.C. Early-stage and preclinical Alzheimer disease. Alzheimer Dis Assoc Disord 2005, 19:163-165.
111. Ringman J.M., Schulman H., Becker C., Jones T., Bai Y., Immermann F., et al. Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations. Arch Neurol 2012, 69:96-104.
112. Ringman J.M., Elashoff D., Geschwind D.H., Welsh B.T., Gylys K.H., Lee C., et al. Plasma signaling proteins in persons at genetic risk for Alzheimer Disease: influence of APOE genotype. Arch Neurol 2012, 69:757-764.
113. Ijsselstijn L., Dekker L.J., Stingl C., van der Weiden M.M., Hofman A., Kros J.M., et al. Serum levels of pregnancy zone protein are elevated in presymptomatic Alzheimer's disease. J Proteome Res 2011, 10:4902-4910.
114. Thambisetty M., Tripaldi R., Riddoch-Contreras J., Hye A., An Y., Campbell J., et al. Proteome-based plasma markers of brain amyloid-β deposition in non-demented older individuals. J Alzheimers Dis 2010, 22:1099-1109.